GlassScriptPhysician profile
Charles V Tran
NPI 1396159836
$360.75
in general payments reported to CMS, 2019-2025
12 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.20 · 2020: $11.66 · 2022: $20.14 · 2023: $49.42 · 2024: $145 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.65 | 2024-2025 | |
| Abbvie INC. | $53.33 | 2023-2025 | Ubrelvy |
| Astellas Pharma US INC | $42.49 | 2019-2023 | Myrbetriq |
| Abiomed | $42.47 | 2024 | Impella |
| Medtronic, INC. | $20.45 | 2025 | Inceptiv |
| Lilly USA, LLC | $20.14 | 2022 | |
| Dexcom, INC. | $19.24 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $16.81 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.83 | 2025 | Jardiance |
| Novo Nordisk INC | $14.35 | 2023 | Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $14.33 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.